HEALTH

Times Staff and Wire Reports

Amgen's Neupogen OKd for HIV Treatment in Britain: Although Neupogen won approval there for treating people with advanced HIV infection, it must finish undergoing clinical trials before the U.S. Food and Drug Administration will consider approving it for AIDS treatment in the United States. Thousand Oaks-based Amgen Inc.'s best-selling drug has already been approved by the FDA for use in patients undergoing chemotherapy, bone marrow transplants and an alternative to marrow transplants called peripheral blood progenitor cell treatment. Neupogen, with annual sales of about $830 million in 1994, treats neutropenia, a condition common to AIDS patients that increases the risk of infection.

Copyright © 2019, Los Angeles Times
EDITION: California | U.S. & World
58°